The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone
Fred Saad, Dean Ruether, Scott Ernst, Scott North, Tina Cheng, Paul Perrotte, Pierre Karakiewicz, Eric WinquistVolume:
102
Année:
2008
Langue:
english
Pages:
5
DOI:
10.1111/j.1464-410x.2008.07733.x
Fichier:
PDF, 147 KB
english, 2008